This pilot study shows that aliskiren with ACE-inhibitor/ARB therapy allows a clinically significant (22% at month 6) and persistent (up to month 12) decrease in proteinuria. The antiproteinuric effect was at least in part unrelated to the antihypertensive effect and small decrease in eGFR and instead may depend on enhanced suppression of intrarenal angiotensin II with more effective correction of glomerular hypertension.The magnitude of antiproteinuric response was greater in younger patients and those with higher sodium excretion and therefore intake.

Antiproteinuric Response to Add-on Aliskiren in Proteinuric Patients Treated With Dual Blockade of the Renin-Angiotensin System: A 12-Month Prospective Uncontrolled Study

RUSSO, DOMENICO;
2011

Abstract

This pilot study shows that aliskiren with ACE-inhibitor/ARB therapy allows a clinically significant (22% at month 6) and persistent (up to month 12) decrease in proteinuria. The antiproteinuric effect was at least in part unrelated to the antihypertensive effect and small decrease in eGFR and instead may depend on enhanced suppression of intrarenal angiotensin II with more effective correction of glomerular hypertension.The magnitude of antiproteinuric response was greater in younger patients and those with higher sodium excretion and therefore intake.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11588/575935
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact